EDGE Edge Therapeutics

EQUITY ALERT: Rosen Law Announces Filing of Securities Class Action Lawsuit Against Edge Therapeutics, Inc. – EDGE

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Edge Therapeutics, Inc. (NASDAQ: EDGE) from December 29, 2017 through March 27, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Edge Therapeutics investors under the federal securities laws.

To join the Edge Therapeutics class action, go to http://www.rosenlegal.com/cases-1330.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics’ lead product candidate, EG-1962, would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result, Edge Therapeutics’ financial statements and defendants’ statements about the company’s business, operations, and prospects, were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 22, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1330.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm was Ranked No. 1 by Institutional Shareholder Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

EN
27/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edge Therapeutics

 PRESS RELEASE

PDS Biotechnology Announces Participation in Noble Capital Markets Vir...

PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series

 PRESS RELEASE

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101...

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the company’s previously ...

 PRESS RELEASE

PDS Biotechnology to Participate in Upcoming Healthcare Investor Confe...

PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcar...

 PRESS RELEASE

PDS Biotechnology Announces Participation in Noble Capital Markets C-S...

PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series FLORHAM PARK, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.  The interview was led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D.  Joining Ahu was Frank...

 PRESS RELEASE

PDS Biotechnology Corporation Announces Closing of Approx. $19 Million...

PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of common s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch